Dapagliflozin and acute heart failure
Phase 3
Not yet recruiting
- Conditions
- Heart Failure.Systolic (congestive) heart failureI50.0
- Registration Number
- IRCT20150617022794N3
- Lead Sponsor
- Semnan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Acute heart failure
BNP>100 pg/ml
receiving IV furosemide
Evidence of congestion
Exclusion Criteria
Serum glucose < 80 mg/dL
Type 1 diabetes mellitus
Systolic blood pressure < 90 mmHg
Requirement of inotropic therapy
hypersensitivity to SGLT-2 inhibitors
Already receiving an SGLT2 inhibitor
Pregnancy
History of DKA
Acute MI
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Dapagliflozin's efficacy in acute systolic heart failure (I50.0)?
How does Dapagliflozin compare to standard-of-care treatments for acute heart failure in phase III trials?
Which biomarkers are associated with response prediction to Dapagliflozin in acute heart failure patients?
What are the potential adverse events and management strategies for Dapagliflozin in acute heart failure?
Are there combination therapies or competitor drugs showing improved outcomes for systolic heart failure compared to Dapagliflozin?